Pages that link to "Q71646845"
Jump to navigation
Jump to search
The following pages link to Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis (Q71646845):
Displaying 36 items.
- Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions (Q24187480) (← links)
- Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease (Q24240101) (← links)
- Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease (Q24245681) (← links)
- Lansoprazole for long-term maintenance therapy of erosive esophagitis: double-blind comparison with ranitidine (Q30446809) (← links)
- Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. (Q31805491) (← links)
- Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline (Q33675495) (← links)
- Overview of medical therapy for gastroesophageal reflux disease (Q33850185) (← links)
- Economic evaluation of long-term management strategies for erosive oesophagitis (Q33867824) (← links)
- Economic considerations in the treatment of gastroesophageal reflux disease: a review (Q34127313) (← links)
- Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders (Q34475730) (← links)
- Lansoprazole for maintenance of remission of erosive oesophagitis (Q34636638) (← links)
- What is heartburn worth? A cost-utility analysis of management strategies (Q34745082) (← links)
- Esomeprazole tablet vs omeprazole capsule in treating erosive esophagitis (Q35010994) (← links)
- An assessment of human gastric fluid composition as a function of PPI usage (Q35294176) (← links)
- Review article: approaches to the long-term management of adults with GERD-proton pump inhibitor therapy, laparoscopic fundoplication or endoscopic therapy? (Q35630060) (← links)
- A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials (Q35745058) (← links)
- Early effects of Lansoprazole orally disintegrating tablets on intragastric pH in CYP2C19 extensive metabolizers (Q37240401) (← links)
- Stronger inhibition of gastric acid secretion by lafutidine, a novel H2 receptor antagonist, than by the proton pump inhibitor lansoprazole (Q37248763) (← links)
- Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group (Q37415335) (← links)
- Response of Regurgitation to Proton Pump Inhibitor Therapy in Clinical Trials of Gastroesophageal Reflux Disease (Q37871345) (← links)
- Deprescribing versus continuation of chronic proton pump inhibitor use in adults. (Q38903118) (← links)
- Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers (Q39341299) (← links)
- Evidence for therapeutic equivalence of lansoprazole 30mg and esomeprazole 40mg in the treatment of erosive oesophagitis (Q39412138) (← links)
- Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients (Q39412700) (← links)
- Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders (Q39453608) (← links)
- Flavor and taste of lansoprazole strawberry-flavored delayed-release oral suspension preferred over ranitidine peppermint-flavored oral syrup: in children aged between 5-11 years (Q40523315) (← links)
- Lansoprazole-associated microscopic colitis: a case series (Q44211920) (← links)
- Comparing the acid-suppressive effects of three brands of generic lansoprazole with the original: pharmacokinetic bioequivalence tests do not necessarily guarantee pharmacodynamic equivalence (Q46192189) (← links)
- Guidance on the use of over-the-counter proton pump inhibitors for the treatment of GERD. (Q51581340) (← links)
- Taste comparisons for lansoprazole strawberry-flavoured delayed-release orally disintegrating tablet and ranitidine peppermint-flavoured syrup in children (Q51751930) (← links)
- An evidence-based appraisal of reflux disease management--the Genval Workshop Report (Q61537811) (← links)
- Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group (Q73234052) (← links)
- Effect of 7-day therapy with different doses of the proton pump inhibitor lansoprazole on the intragastric pH in healthy human subjects (Q78107335) (← links)
- [Therapeutic strategies in non-erosive gastro-oesophageal reflux disease] (Q80606073) (← links)
- Proton pump inhibitors: use, misuse and concerns about long-term therapy (Q85624434) (← links)
- Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease (Q92663343) (← links)